Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).

Low-dose indacaterol/mometasone improves FEV1 in adolescents, adults with asthma

Elaine Soliven
11 Oct 2019
Dr Peter Andrea

The use of low-dose indacaterol acetate/mometasone furoate (IND/MF), a long-acting β2-agonist/inhaled corticosteroid (LABA/ICS) combination, significantly improves trough FEV1* in symptomatic patients with poorly controlled asthma, according to the QUARTZ** study presented at ERS 2019.

This phase III, multicentre, double-blind, double-dummy, parallel-group trial involved 64 adolescents and 738 adults (aged ≥12 and ≤75 years) with inadequately controlled asthma who were taking low-dose ICS, with or without LABA, for ≥1 month. They were randomized 1:1 to receive either IND/MF (150/80 μg; n=398) or MF alone (200 μg; n=404) once daily for 12 weeks. [ERS 2019, abstract RCT3780]

At 12 weeks, patients treated with IND/MF had a significantly greater improvement from baseline in trough FEV1 compared with MF alone (0.234 vs 0.051 L; mean difference, 0.182 L, 95 percent confidence interval [CI], 0.148–0.217; p<0.001).

Patients on IND/MF also reported significant improvement from baseline in asthma control, as shown by Asthma Control Questionnaire (ACQ)-7 score, than those on MF alone at 12 weeks (-0.947 vs -0.730; mean difference, -0.218, 95 percent CI, -0.293 to -0.143; p<0.001).

In a responder analysis, more patients on IND/MF achieved an improvement of ≥0.5 units in the ACQ-7 score after 12 weeks compared with those on MF alone (74.7 percent vs 64.9 percent; odds ratio, 1.69, 95 percent CI, 1.23–2.33).

Adverse events (AEs) occurred at a lower rate in the IND/MF arm (32.3 percent vs 38.3 percent), while serious AEs occurred at a comparable rate between the IND/MF and MF arms (1.3 percent vs 1.8 percent).

“GINA*** 2019 recommends the addition of LABA to ICS monotherapy as the maintenance controller therapy in patients with inadequately controlled asthma. The combination helps in achieving asthma control [in terms of ACQ-7 score] by reducing symptoms and improving lung function [in terms of trough FEV1 score] in these patients,” said Dr Peter Andrea from Novartis Pharmaceuticals Corporation at East Hanover in New Jersey, US.

“To our knowledge, this is the first study to compare a low-dose ICS/LABA fixed-dose combination once-daily to low-dose ICS monotherapy in adult and adolescent patients with inadequately controlled asthma, … [and] this study provided evidence for benefits across a range of lung function and symptomatic endpoints,” Andrea said.

“Overall, results support the use of IND/MF 150/80 µg once-daily as a potential treatment in adult and adolescent patients with asthma inadequately controlled on low-dose ICS (+/- controller),” he concluded.

 

*FEV1: Forced expiratory volume in 1 second

**QUARTZ: Study of QMF149 (150/80 µg) compared with MF Twisthaler® (200 µg) in patients with asthma

***GINA: Global Initiative for Asthma
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).